-
Gaps In Screening Among Medicare Patients With A Ruptured Abdominal Aortic Aneurysm
Mar 10, 2025, 14:00 PM -
Estimating the Cost at which GLP-1 RAs Would become Cost-Effective for Multimorbid Type 2 Diabetes Patients in Canada
Mar 10, 2025, 14:00 PM -
Differential Item Functioning With the National Eye Institute Visual Function Questionnaire-25 in Patients With Vitreomacular Traction
Mar 10, 2025, 14:00 PM -
National Assessment of Depression Between Early vs Late Adolescents Using National Survey of Child Health Survey
Mar 10, 2025, 14:00 PM -
Advancing Health Equity in Economic Evaluations, With The Distributional Generalized Risk-Adjusted Cost-Effectiveness (DGRACE) Model
Mar 10, 2025, 14:00 PM -
Colorectal Cancer Screening Initiation Among Newly Age-Eligible Medicaid-Insured Individuals in Texas
Mar 10, 2025, 14:00 PM -
Pioneering the Integration of Health-Equity Variables Into an Administrative Claims Database: A Step Forward in the Journey to Supporting Underserved Populations
Mar 10, 2025, 14:00 PM -
Real-World Patient Characteristics and Treatment Patterns in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients With Long-Term Survivorship
Mar 10, 2025, 14:00 PM -
Evidence for the Cumulative Impact of Social Determinants of Health (SDOH) on Cancer Mortality: A Scoping Review
Mar 10, 2025, 14:00 PM -
Characterization of Economic Burden in Individuals With Narcolepsy or Idiopathic Hypersomnia at Higher Risk of Sodium-Associated Negative Clinical Outcomes in the United States
Mar 10, 2025, 14:00 PM -
A Systematic Literature Review of Health Economic Models Structures for Chronic Rhinosinusitis with Nasal Polyps
Mar 10, 2025, 14:00 PM -
Impact of Valbenazine on Improvements in Disability and Functional Impairment in Patients With Tardive Dyskinesia (TD): Sheehan Disability Scale (SDS) Results From a Phase 4 Randomized Withdrawal Study (NCT03891862)
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness Analysis of Axicabtagene Ciloleucel as a Second-Line Treatment for Diffuse Large B-Cell Lymphoma in China
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness of Mineralocorticoid Receptor Antagonists in Heart Failure With Reduced Ejection Fraction: The Brazilian Case With Bayesian Networks and Markov Influence Diagrams
Mar 10, 2025, 14:00 PM -
Payer Archetypes and Decision-Making in the United States (US): A framework for Generalised Cost-Effectiveness Analysis (GCEA) Value Elements to Optimize Patient Access and Equity
Mar 10, 2025, 14:00 PM -
Impact of Single-Patient use Electrocardiogram Monitoring in the Cost of Care and Infection Prevention of CABG Surgery Patients in the USA
Mar 10, 2025, 14:00 PM -
Payer Perceptions on Creating a National Value assessment Body in the US
Mar 10, 2025, 14:00 PM -
The Association Between COVID-19 Vaccination History and the Incidence of COVID-19 and Healthcare Resource Use in Rural Residents in Japan
Mar 10, 2025, 14:00 PM -
Moving Beyond Partitioned Survival Models in Oncology Submissions: Incorporation of Canada's Drug Agency Guidance on Model Structure
Mar 10, 2025, 14:00 PM -
The Prevalence Of Multi-Comorbid Patients In The US: The Potential For Benefit Being Greater Than Bargained For And The Need For Multi-Indication Value Assessment
Mar 10, 2025, 14:00 PM
